DNA Class A Ginkgo Bioworks Holdings, Inc. Class A Common Stock
NYSE · Life Sciences Tools & Services · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$12.35
· of 52w range
· above low
· to high
$5.3752w low
$17.5852w high
Market Cap (MRQ)
$787M
P/E
-2.3
EPS
$-5.64
Revenue
$170M
your badges
52W Range
$5–$18
Analyst Rating
SELL
Price Target
$7
P/E
-2.3
ROE
-55.8%
Net Profit Margin
-260.0%
Your badge strip is empty — pin a metric anywhere on this page.
DNA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$12.35
Market Cap (MRQ)
$787M
P/E
-2.3
EPS
$-5.64
Revenue
$170M
ROE
-55.8%
52W Range
$5–$18
DNA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Aug. 20, 2024 | 1-for-40 | Reverse |
About Ginkgo Bioworks Holdings, Inc. Class A Common Stock Company overview from Wikipedia
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
History
In 2014, Ginkgo was the first biotechnology company to join the Y Combinator start-up accelerator program.
On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform. 2020 also saw the company acquire property worth $25 million from Marcus Partners for the construction of a new 219,000 square foot laboratory building, after razing existing structures, located in the Raymond L Flynn Marine Park. As of 2021, the company also occupied 200,000 square feet of the Innovation and Design Building (aka IDB) in the Park. Ginkgo also occupied facilities in Cambridge, where most MIT-spin outs resided at the time.
Growth of Ginkgo up to 2021 had been driven by "robust venture capital funding" and entry into the COVID-19 testing market. This included $45 million from Viking Global in 2015.
On 11 May 2021, Ginkgo Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.
On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be "DNA". The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began on September 17, 2021. The investment management firm Baillie Gifford became the largest shareholder (15%) with the purchase of 167.75 million shares on 31 March 2022.
On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform.
On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from real-time metabolite monitoring company, Bitome.
On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.
On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginkgo will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks.
On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.
In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR (short for Engineered Nucleotide Detection and Ranking) could be used to provide an early warning of bioweapons and other man-made biological threats.
Fraud allegations
On 6 October 2021, a market research firm published a report accusing Ginkgo of embellishing its revenue in a complex scheme highly dependent on related-party transactions. The report prompted an inquiry into Ginkgo by the United States Department of Justice. In November 2021, Ginkgo was sued in a shareholder lawsuit alleging it misrepresented its revenue sources in statements regarding its merger with a special-purpose acquisition company. As of 2021, the company could not name a single significant product that is manufactured and sold using its organisms.
In March 2023, the former Attorney General of Louisiana launched an investigation into the officers and directors of Ginkgo.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryLife Sciences Tools & Services
employees485
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$170M2019-12-31 → 2025-12-31
EPS$-5.642019-12-31 → 2025-12-31
Free Cash Flow$-179M2022-12-31 → 2025-12-31
Net margin-260.0%2022-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | DNA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -2.35Y avg ≈-49.3 | ≈-49.3 | · | · | |
| P/S (TTM) | 7.05Y avg ≈202.7 | ≈202.7 | · | · | |
| P/B (MRQ) | 1.95Y avg ≈49.7 | ≈49.7 | · | · | |
| Price / FCF (TTM) | -4.55Y avg ≈-206.6 | ≈-206.6 | · | · | |
| Price / Cash Flow (TTM) | -4.65Y avg ≈-242.4 | ≈-242.4 | · | · | |
| Price / Tangible Book (MRQ) | 2.15Y avg ≈115.0 | ≈115.0 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | DNA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -259.9%5Y avg ≈-309.5% | ≈-309.5% | · | · | |
| EBITDA Margin | -185.3%5Y avg ≈-309.5% | ≈-309.5% | · | · | |
| Pretax Margin (TTM) | -264.1%5Y avg ≈-306.2% | ≈-306.2% | · | · | |
| Net Profit Margin (TTM) | -260.0%5Y avg ≈-305.1% | ≈-305.1% | · | · | |
| ROA | -25.1%5Y avg ≈-48.7% | ≈-48.7% | · | · | |
| ROE | -55.8%5Y avg ≈-84.1% | ≈-84.1% | · | · | |
| ROIC | -61.8%5Y avg ≈-86.3% | ≈-86.3% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | DNA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 4.65Y avg ≈6.3 | ≈6.3 | · | · | |
| Quick Ratio | 4.75Y avg ≈6.0 | ≈6.0 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | DNA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -25.1%5Y avg ≈55.9% | ≈55.9% | · | · | |
| Revenue CAGR 3Y | -29.1%5Y avg ≈3.1% | ≈3.1% | · | · | |
| Revenue CAGR 5Y | 17.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | DNA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.15Y avg ≈0.2 | ≈0.2 | · | · | |
| Receivables Turnover | 7.45Y avg ≈7.2 | ≈7.2 | · | · | |
| Revenue / Employee | ≈$350.8K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
2.6%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.75 | $-0.92 | 18.4% | |
| March 31, 2026 | $-1.39 | $-1.09 | -27.4% | |
| Dec. 31, 2025 | $-1.41 | $-1.47 | 4.1% | |
| Sept. 30, 2025 | $-1.45 | $-1.25 | -15.8% | |
| June 30, 2025 | $-1.10 | $-1.58 | 30.5% | |
| March 31, 2025 | $-1.68 | $-1.79 | 6.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $170M | $227M | $251M | $478M | $314M | $77M | $54M | |
| R&D Expense | $244M | $424M | $581M | $1.05B | $1.15B | $160M | $96M | |
| SG&A Expense | $183M | $246M | $385M | $1.43B | $863M | $38M | $29M | |
| Operating Expenses | $485M | $787M | $1.12B | $2.69B | $2.14B | $214M | $126M | |
| Operating Income | $-315M | $-560M | $-864M | $-2.21B | $-1.83B | $-137M | $-72M | |
| Interest Expense | · | · | $93.0K | $106.0K | $2M | $2M | $2M | |
| Other Non-op | $2M | $12M | $-29M | $88M | $-10M | $12M | · | |
| Pretax Income | $-314M | $-548M | $-893M | $-2.12B | $-1.84B | $-125M | $-120M | |
| Income Tax | $-837.0K | $-479.0K | $-71.0K | $-15M | $-1M | $2M | $22.0K | |
| Net Income | $-313M | $-547M | $-893M | $-2.10B | $-1.83B | $-127M | $-119M | |
| EPS (Basic) | $-5.64 | $-10.54 | $-18.37 | $-50.15 | $-1.35 | $-0.10 | $-0.10 | |
| EPS (Diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 | $-0.10 | $-0.10 | |
| Shares (Basic) | 55,457,676 | 51,894,639 | 48,610,507 | 41,976,537 | 1,359,849,000 | 1,274,766,915 | 1,149,000,417 | |
| Shares (Diluted) | 55,457,676 | 51,894,639 | 48,610,507 | 41,995,972 | 1,360,373,000 | 1,274,766,915 | 1,149,000,417 | |
| EBITDA | $-315M | $-560M | $-864M | $-2.21B | · | · | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $167M | $562M | $944M | $1.32B | $1.55B | $381M | $495M | |
| Short-term Investments | $255M | $0 | · | · | · | · | · | |
| Receivables | $24M | $22M | $17M | $81M | $132M | $17M | · | |
| Inventory | · | · | $46.0K | $4M | $3M | $3M | · | |
| Prepaid Expense | $25M | $19M | $40M | $52M | $34M | $21M | · | |
| Other Current Assets | · | · | $362.0K | $487.0K | $698.0K | $680.0K | · | |
| Current Assets | $472M | $603M | $1.00B | $1.45B | $1.72B | $427M | · | |
| PP&E (Net) | $167M | $204M | $188M | $315M | $146M | $121M | · | |
| PP&E (Gross) | $355M | $365M | $309M | $408M | $207M | $155M | · | |
| Accum. Depreciation | $188M | $161M | $121M | $93M | $61M | $34M | · | |
| Goodwill | · | $0 | $49M | $60M | $21M | $2M | $2M | |
| Intangibles | $53M | $73M | $83M | $111M | $22M | $3M | · | |
| Other Non-current Assets | $9M | $55M | $58M | $89M | $44M | $6M | · | |
| Total Assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675M | · | |
| Accounts Payable | $11M | $14M | $9M | $10M | $8M | $14M | · | |
| Accrued Liabilities | · | · | · | $115M | $93M | $31M | · | |
| Short-term Debt | · | · | · | · | · | $300.0K | · | |
| Current Liabilities | $96M | $107M | $164M | $173M | $135M | $73M | · | |
| Capital Leases | $417M | $439M | $222M | $413M | $0 | · | · | |
| Other Non-current Liabilities | $23M | $17M | $24M | $31M | $36M | $3M | · | |
| Total Liabilities | $611M | $661M | $568M | $803M | $504M | $205M | · | |
| Common Stock | $6.0K | $5.0K | $5.0K | $190.0K | $161.0K | $129.0K | · | |
| Paid-in Capital | $6.66B | $6.56B | $6.39B | $6.14B | $3.80B | $929M | · | |
| Retained Earnings | $-6.15B | $-5.84B | $-5.29B | $-4.40B | $-2.30B | $-468M | · | |
| AOCI | $2M | $-2M | $1M | $-3M | $-2M | $0 | · | |
| Stockholders' Equity | $509M | $716M | $1.10B | $1.74B | $1.57B | $470M | · | |
| Liabilities + Equity | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675M | · | |
| Shares Outstanding | 58,207,298 | 54,365,785,000 | 50,032,873 | 47,299,399 | 40,284,804 | 1,288,596,000 | · |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $59M | $63M | $71M | $43M | $29M | $14M | $11M | |
| Stock-based Comp | $82M | $112M | $230M | $1.93B | $1.61B | $476.0K | $771.0K | |
| Deferred Tax | $-1M | $-936.0K | $-801.0K | $-15M | $0 | $0 | · | |
| Amort. of Intangibles | $19M | $18M | $16M | $6M | $1M | $500.0K | $500.0K | |
| Restructuring | $11M | $19M | · | · | · | · | · | |
| Operating Cash Flow | $-171M | $-320M | $-296M | $-252M | $-254M | $-136M | $-45M | |
| CapEx | $8M | $63M | $41M | $52M | $57M | $58M | $22M | |
| Investing Cash Flow | $-240M | $-62M | $-81M | $-67M | $-73M | $-67M | $-75M | |
| Stock Issued | $19M | $0 | $0 | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $408.0K | |
| Net Stock Activity | $19M | · | · | · | · | · | · | |
| Financing Cash Flow | $18M | $-2M | $-3M | $95M | $1.53B | $90M | $410M | |
| Net Change in Cash | $-393M | $-384M | $-380M | $-223M | $1.21B | $-113M | $291M | |
| Taxes Paid | $192.0K | $0 | $23.0K | $981.0K | $9M | $0 | · | |
| Free Cash Flow | $-179M | $-382M | $-336M | $-304M | · | · | · | |
| Levered FCF | · | · | $-336M | $-305M | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -185.3% | -246.5% | -343.8% | -462.4% | · | · | · | |
| Net Margin | -183.8% | -240.9% | -355.1% | -440.6% | · | · | · | |
| Pretax Margin | -184.3% | -241.2% | -355.1% | -444.1% | · | · | · | |
| EBITDA Margin | -185.3% | -246.5% | -343.8% | -462.4% | · | · | · | |
| ROA | -25.1% | -36.0% | -42.5% | -91.3% | · | · | · | |
| ROE | -55.8% | -72.3% | -76.0% | -132.4% | · | · | · | |
| ROIC | -61.8% | -78.1% | -78.8% | -126.3% | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.6 | 6.1 | 8.4 | · | · | · | |
| Quick Ratio | 4.7 | 5.4 | 5.9 | 8.1 | · | · | · | |
| Interest Coverage | · | · | -9294.7 | -20839.2 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | |
| Receivables Turnover | 7.4 | 11.6 | 5.1 | 4.5 | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.74 | $13.17 | $0.55 | $0.92 | · | · | · | |
| Revenue / Share | $3.07 | $4.38 | $0.13 | $0.28 | · | · | · | |
| Cash Flow / Share | $-3.08 | $-6.16 | $-0.15 | $-0.15 | · | · | · | |
| Cash / Share | $2.87 | $10.33 | $0.47 | $0.70 | · | · | · | |
| EPS (TTM) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -25.1% | -9.7% | -47.4% | 52.2% | 309.4% | · | · | |
| Revenue CAGR 3Y | -29.1% | -10.2% | 48.6% | · | · | · | · | |
| Revenue CAGR 5Y | 17.3% | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170M | $227M | $251M | $478M | $314M | · | · | |
| Net Income TTM | $-313M | $-547M | $-893M | $-2.10B | $-1.83B | · | · | |
| Market Cap | $484M | $534M | $135.29B | $127.90B | · | · | · | |
| P/E | -1.5 | -0.9 | -3.7 | -1.3 | -239.1 | · | · | |
| P/S | 2.8 | 2.4 | 538.0 | 267.7 | · | · | · | |
| P/B | 1.0 | 0.7 | 123.3 | 73.7 | · | · | · | |
| P / Tangible Book | 1.1 | 0.8 | 140.2 | 81.7 | 351.4 | · | · | |
| P / Cash Flow | -2.8 | -1.7 | -457.8 | -507.1 | · | · | · | |
| P / FCF | -2.7 | -1.4 | -402.3 | -420.1 | · | · | · | |
| Earnings Yield | -67.9% | -107.3% | -27.2% | -74.3% | -0.42% | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | $19M | $33M | $39M | $39M | $38M | $44M | $89M | $56M | $38M | $35M | $55M | $81M | $81M | $98M | $66M | |
| Cost of Revenue | $2M | $3M | · | · | $5M | $4M | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $46M | $50M | $50M | $69M | $53M | $71M | $76M | $77M | $134M | $136M | $117M | $157M | $144M | $163M | $178M | $261M | |
| SG&A Expense | $31M | $38M | $46M | $45M | $35M | $40M | $57M | $52M | $66M | $70M | $89M | $82M | $102M | $111M | $121M | $435M | |
| Operating Expenses | $79M | $91M | $104M | $129M | $97M | $119M | $147M | $144M | $279M | $216M | $213M | $342M | $265M | $296M | $329M | $721M | |
| Operating Income | $-59M | $-71M | $-71M | $-90M | $-58M | $-81M | $-104M | $-55M | $-223M | $-178M | $-178M | $-286M | $-184M | $-216M | $-231M | $-655M | |
| Other Non-op | $1M | $-5M | $-11M | $9M | $5M | $-2M | $-4M | $-2M | $6M | $12M | $-34M | $-17M | $11M | $11M | $43M | $-15M | |
| Pretax Income | $-57M | $-76M | $-81M | $-81M | $-53M | $-83M | $-108M | $-57M | $-217M | $-166M | $-212M | $-303M | $-173M | $-205M | $-188M | $-670M | |
| Income Tax | $128.0K | $-80.0K | $-643.0K | $1.0K | $-283.0K | $88.0K | $-325.0K | $-375.0K | $190.0K | $31.0K | $-198.0K | $-22.0K | $67.0K | $82.0K | $-15M | $-28.0K | |
| Net Income | $-47M | $-83M | $-81M | $-81M | $-60M | $-91M | $-108M | $-56M | $-217M | $-166M | $-212M | $-303M | $-173M | $-205M | $-175M | $-670M | |
| EPS (Basic) | $-0.75 | $-1.39 | $-1.41 | $-1.45 | $-1.10 | $-1.68 | $-1.92 | $-1.08 | $-4.23 | $-3.31 | $-11.96 | $-6.21 | $-0.09 | $-0.11 | $-48.96 | $-0.41 | |
| EPS (Diluted) | · | · | $-1.41 | $-1.45 | $-1.10 | $-1.68 | $-1.91 | $-1.08 | $-4.23 | $-3.32 | $-11.96 | $-6.21 | $-0.09 | $-0.11 | $-49.01 | $-0.41 | |
| Shares (Basic) | 62,094,356 | 59,563,454 | · | 55,633,718 | 54,858,982 | 54,241,619 | · | 52,240,559 | 51,370,029 | 50,111,460 | · | 48,770,000 | 1,933,437,000 | 1,914,963,000 | · | 1,630,911,000 | |
| Shares (Diluted) | · | · | · | 55,633,718 | 54,858,982 | 54,241,619 | · | 52,246,129 | 51,375,599 | 50,133,366 | · | 48,770,000 | 1,933,437,000 | 1,916,637,000 | · | 1,630,911,000 | |
| EBITDA | $-59M | $-71M | · | $-90M | $-66M | $-89M | · | $-55M | $-223M | $-178M | · | $-286M | $-184M | $-216M | · | $-653M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85M | $144M | $167M | $111M | $204M | $312M | $562M | $616M | $730M | $840M | $944M | $1.05B | $1.11B | $1.21B | $1.32B | $1.30B | |
| Short-term Investments | · | · | $255M | $384M | $356M | $13M | $0 | · | · | · | · | · | · | · | · | · | |
| Receivables | $13M | $20M | $24M | $21M | $22M | $26M | $22M | $23M | $19M | $24M | · | $62M | $68M | $83M | · | $114M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | · | $70.0K | $391.0K | $3M | · | $6M | |
| Prepaid Expense | $17M | $16M | $25M | $22M | $26M | $20M | $19M | $22M | $34M | $38M | · | $29M | $48M | $34M | · | $38M | |
| Current Assets | $333M | $410M | $472M | $506M | $523M | $565M | $603M | $662M | $783M | $903M | · | $1.14B | $1.22B | $1.33B | · | $1.46B | |
| PP&E (Net) | $157M | $163M | $168M | $177M | $186M | $198M | $204M | $211M | $211M | $196M | · | $202M | $294M | $314M | · | $188M | |
| PP&E (Gross) | $355M | $352M | $358M | $359M | $360M | $361M | $365M | $362M | $347M | $326M | · | $322M | $413M | $421M | · | $271M | |
| Accum. Depreciation | $198M | $189M | $191M | $182M | $173M | $163M | $161M | $151M | $136M | $130M | · | $121M | $118M | $107M | · | $83M | |
| Goodwill | · | · | · | · | · | · | $0 | $0 | $0 | $48M | $49M | $58M | $59M | $59M | $60M | $29M | |
| Intangibles | $44M | $49M | $57M | $62M | $66M | $69M | $73M | $80M | $91M | $77M | · | $100M | $105M | $109M | · | $48M | |
| Other Non-current Assets | $1M | $40M | $47M | $47M | $47M | $47M | $55M | $60M | $60M | $61M | · | $97M | $98M | $97M | · | $44M | |
| Total Assets | $990M | $1.03B | $1.12B | $1.19B | $1.23B | $1.29B | $1.38B | $1.48B | $1.63B | $1.58B | · | $2.03B | $2.29B | $2.42B | · | $1.87B | |
| Accounts Payable | $10M | $16M | $11M | $11M | $11M | $11M | $14M | $16M | $23M | $27M | · | $11M | $14M | $22M | · | $11M | |
| Current Liabilities | $73M | $80M | $96M | $115M | $97M | $116M | $107M | $114M | $166M | $169M | · | $168M | $163M | $192M | · | $125M | |
| Capital Leases | $404M | $411M | $417M | $423M | $429M | $435M | $439M | $446M | $452M | $234M | · | $404M | $411M | $404M | · | · | |
| Other Non-current Liabilities | $16M | $22M | $23M | $17M | $18M | $15M | $17M | $18M | $21M | $25M | · | $19M | $20M | $29M | · | $35M | |
| Total Liabilities | $570M | $590M | $611M | $629M | $618M | $646M | $661M | $683M | $792M | $594M | · | $774M | $788M | $810M | · | $431M | |
| Common Stock | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $206.0K | $202.0K | · | $198.0K | $196.0K | $194.0K | · | $165.0K | |
| Paid-in Capital | $6.70B | $6.67B | $6.66B | $6.63B | $6.60B | $6.58B | $6.56B | $6.53B | $6.51B | $6.45B | · | $6.33B | $6.28B | $6.21B | · | $5.67B | |
| Retained Earnings | $-6.28B | $-6.23B | $-6.15B | $-6.07B | $-5.99B | $-5.93B | $-5.84B | $-5.73B | $-5.67B | $-5.46B | · | $-5.08B | $-4.78B | $-4.60B | · | $-4.23B | |
| AOCI | $950.0K | $1M | $2M | $2M | $2M | $-850.0K | $-2M | $263.0K | $-2M | $-2M | · | $-3M | $-1M | $-2M | · | $-8M | |
| Stockholders' Equity | $420M | $443M | $509M | $560M | $613M | $647M | $716M | $798M | $833M | $987M | $1.10B | $1.25B | $1.50B | $1.61B | $1.74B | $1.43B | |
| Liabilities + Equity | $990M | $1.03B | $1.12B | $1.19B | $1.23B | $1.29B | $1.38B | $1.48B | $1.63B | $1.58B | · | $2.03B | $2.29B | $2.42B | · | $1.87B | |
| Shares Outstanding | 63,711,102 | 61,660,788 | 58,207,298 | 56,836,246 | 55,425,334 | 54,698,246 | 54,365,785 | 53,082,000 | 2,078,737,000 | 2,033,624,000 | 50,032,873 | 1,972,725,000 | 1,954,704,000 | 1,933,880,000 | 47,299,399 | 1,648,263,224 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $13M | $14M | $14M | $16M | $15M | $16M | $17M | $17M | $13M | $13M | $21M | $18M | $19M | $16M | $8M | |
| Stock-based Comp | $8M | $16M | $21M | $18M | $22M | $17M | $21M | $14M | $37M | $41M | $43M | $53M | $61M | $73M | $108M | $563M | |
| Amort. of Intangibles | $4M | $4M | $5M | $5M | $4M | $4M | $5M | $5M | $5M | $3M | $3M | $4M | $4M | $4M | $3M | $1M | |
| Restructuring | · | · | $706.0K | $2M | $4M | · | $-666.0K | $3M | $12M | · | · | $0 | $0 | · | · | · | |
| Operating Cash Flow | $-44M | $-47M | $-48M | $-32M | $-40M | $-52M | $-42M | $-104M | $-84M | $-89M | $-58M | $-74M | $-74M | $-91M | $-105M | $-28M | |
| CapEx | $3M | $2M | $5.0K | $0 | $38.0K | $8M | $14M | $15M | $27M | $7M | $3M | $4M | $14M | $19M | $26M | $13M | |
| Investing Cash Flow | $11M | $23M | $95M | $-73M | $-64M | $-199M | $-13M | $-10M | $-27M | $-12M | $-47M | $-3M | $-11M | $-19M | $30M | $-46M | |
| Stock Issued | · | · | $9M | $10M | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $16M | $-19.0K | $8M | $10M | $-98.0K | $-207.0K | $-203.0K | $-465.0K | $-226.0K | $-845.0K | $-632.0K | $-315.0K | $-1M | $-888.0K | $98M | $-280.0K | |
| Net Change in Cash | $-17M | $-24M | $55M | $-94M | $-104M | $-250M | $-56M | $-114M | $-111M | $-102M | $-105M | $-77M | $-87M | $-111M | $24M | $-75M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Free Cash Flow | · | $-49M | · | · | · | $-59M | · | · | · | $-96M | · | · | · | $-110M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -290.5% | -366.5% | · | -231.8% | -132.1% | -184.1% | · | -62.0% | -396.7% | -469.1% | · | -516.7% | -228.6% | -267.3% | · | -983.5% | |
| Net Margin | -231.7% | -424.1% | · | -207.9% | -121.6% | -188.2% | · | -63.3% | -386.4% | -437.2% | · | -546.4% | -215.1% | -254.0% | · | -1007.6% | |
| Pretax Margin | -283.8% | -391.0% | · | -207.9% | -122.1% | -188.1% | · | -63.8% | -386.1% | -437.2% | · | -546.5% | -215.0% | -253.9% | · | -1007.7% | |
| EBITDA Margin | -290.5% | -366.5% | · | -231.8% | -132.1% | -184.1% | · | -62.0% | -396.7% | -469.1% | · | -516.7% | -228.6% | -267.3% | · | -983.5% | |
| ROA | -4.2% | -7.1% | · | -6.0% | -4.2% | -6.3% | · | -3.2% | -11.1% | -8.3% | · | -15.5% | -8.1% | -9.2% | · | -33.3% | |
| ROE | -9.0% | -15.2% | · | -11.9% | -8.3% | -11.1% | · | -5.5% | -18.6% | -12.8% | · | -22.5% | -11.4% | -12.9% | · | -44.8% | |
| ROIC | -14.0% | -16.1% | · | -16.1% | -10.6% | -13.8% | · | -6.9% | -26.8% | -18.0% | · | -22.9% | -12.2% | -13.4% | · | -45.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.6 | 5.2 | · | 4.4 | 5.4 | 4.9 | · | 5.8 | 4.7 | 5.3 | · | 6.8 | 7.5 | 6.9 | · | 11.7 | |
| Quick Ratio | 1.3 | 2.1 | · | 4.5 | 6.0 | 3.0 | · | 5.6 | 4.5 | 5.1 | · | 6.6 | 7.2 | 6.7 | · | 11.3 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.1 | 0.8 | · | 1.7 | 2.4 | 1.9 | · | 2.1 | 1.3 | 0.7 | · | 0.6 | 0.7 | 0.6 | · | 0.8 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.60 | $7.19 | · | $9.85 | $11.06 | $11.84 | · | $15.03 | $0.40 | $0.49 | · | $0.64 | $0.77 | $0.83 | · | $0.87 | |
| Revenue / Share | · | · | · | $0.70 | $0.90 | $0.89 | · | $1.70 | $0.03 | $0.02 | · | $0.03 | $0.04 | $42.11 | · | $0.04 | |
| Cash Flow / Share | · | · | · | · | · | $-0.95 | · | · | · | $-0.04 | · | · | · | $-47.26 | · | · | |
| Cash / Share | $1.33 | $2.33 | · | $1.95 | $3.67 | $5.71 | · | $11.61 | $0.35 | $0.41 | · | $0.53 | $0.57 | $0.62 | · | $0.79 | |
| EPS (TTM) | $-5.64 | $-5.64 | · | $-6.14 | $-5.77 | $-8.90 | · | $-20.59 | $-25.72 | $-21.58 | · | $-55.42 | $-49.62 | $-49.94 | · | $-2.40 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $112M | $131M | · | $160M | $210M | $227M | · | $218M | $184M | $209M | · | $315M | $326M | $390M | · | $528M | |
| Net Income TTM | $-291M | $-304M | · | $-340M | $-315M | $-472M | · | $-651M | $-898M | $-854M | · | $-857M | $-1.22B | $-1.72B | · | $-3.53B | |
| Market Cap | $631M | $378M | · | $829M | $624M | $312M | · | $433M | $27.77B | $94.36B | · | $142.83B | $145.43B | $102.88B | · | $205.70B | |
| P/E | -1.8 | -1.1 | · | -2.4 | -1.9 | -0.6 | · | -0.4 | -0.5 | -2.2 | · | -1.3 | -1.5 | -1.1 | · | -52.0 | |
| P/S | 5.6 | 2.9 | · | 5.2 | 3.0 | 1.4 | · | 2.0 | 150.7 | 452.1 | · | 453.4 | 446.2 | 263.8 | · | 389.7 | |
| P/B | 1.5 | 0.9 | · | 1.5 | 1.0 | 0.5 | · | 0.5 | 33.3 | 95.6 | · | 114.0 | 96.7 | 64.0 | · | 143.4 | |
| P / Tangible Book | 1.7 | 1.0 | · | 1.7 | 1.1 | 0.5 | · | 0.6 | 37.4 | 109.5 | · | 130.5 | 108.6 | 71.4 | · | 151.5 | |
| P / Cash Flow | · | -8.1 | · | · | · | -6.1 | · | · | · | -1057.2 | · | · | · | -1135.8 | · | · | |
| Earnings Yield | -56.9% | -92.0% | · | -42.1% | -51.3% | -156.1% | · | -252.6% | -192.5% | -46.5% | · | -76.5% | -66.7% | -93.9% | · | -1.9% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $170M | $227M | $251M | $478M | $314M |
| Operating Margin % | -185.3% | -246.5% | -343.8% | -462.4% | · |
| Net Income | $-313M | $-547M | $-893M | $-2.10B | $-1.83B |
| Diluted EPS | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.6 | 6.1 | 8.4 | · |
| Quick Ratio | 4.7 | 5.4 | 5.9 | 8.1 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-179M | $-382M | $-336M | $-304M | · |
Institutional owners (13F) 201 filers · $379.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
201
Value held
$379.7M
New positions
31
Exited positions
17
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 31 (-1 vs prior Q) | 17 (-12 vs prior Q) | 71 (+18 vs prior Q) | 37 (-5 vs prior Q) | +4.5M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $42,443,568 | 4,282,903 | 11.18% | Shares |
| VIKING GLOBAL INVESTORS LP | $35,449,338 | 3,577,128 | 9.33% | Shares |
| Erste Asset Management GmbH | $25,902,147 | 2,536,939 | 6.82% | Shares |
| VANGUARD GROUP INC | $24,106,911 | 2,900,952 | 6.35% | Shares |
| BAILLIE GIFFORD & CO | $23,701,242 | 2,391,649 | 6.24% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $20,685,074 | 2,087,293 | 5.45% | Shares |
| Anchorage Capital Group, L.L.C. | $17,306,457 | 1,746,363 | 4.56% | Shares |
| Legal & General Group Plc | $16,543,944 | 1,669,419 | 4.36% | Shares |
| STATE STREET CORP | $14,591,187 | 1,472,370 | 3.84% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $12,112,753 | 1,222,016 | 3.19% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $9,293,628 | 937,803 | 2.45% | Shares |
| Allianz Asset Management GmbH | $7,787,258 | 785,798 | 2.05% | Shares |
| UBS Group AG | $6,854,341 | 691,659 | 1.80% | Shares |
| MILLENNIUM MANAGEMENT LLC | $6,329,279 | 638,676 | 1.67% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $6,160,304 | 621,625 | 1.62% | Shares |
| SB INVESTMENT ADVISERS (UK) LTD | $6,052,324 | 610,729 | 1.59% | Shares |
| GOLDMAN SACHS GROUP INC | $6,019,096 | 607,376 | 1.59% | Shares |
| BANK OF AMERICA CORP /DE/ | $5,409,393 | 545,852 | 1.42% | Shares |
| Prescott Group Capital Management, L.L.C. | $5,369,684 | 541,845 | 1.41% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $5,349,973 | 539,856 | 1.41% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $4,109,677 | 414,700 | 1.08% | Call option |
| NORTHERN TRUST CORP | $4,014,948 | 405,141 | 1.06% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3,910,555 | 394,607 | 1.03% | Shares |
| EXCHANGE TRADED CONCEPTS, LLC | $3,555,540 | 358,783 | 0.94% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $3,480,392 | 351,200 | 0.92% | Shares |
| TUDOR INVESTMENT CORP ET AL | $3,326,886 | 335,710 | 0.88% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $3,097,598 | 312,573 | 0.82% | Shares |
| Coastal Bridge Advisors, LLC | $2,743,256 | 276,817 | 0.72% | Shares |
| Invesco Ltd. | $2,098,175 | 211,723 | 0.55% | Shares |
| BALANCE CAPITAL PARTNERS L.P. | $1,972,179 | 199,009 | 0.52% | Shares |
| ALGERT GLOBAL LLC | $1,784,395 | 180,060 | 0.47% | Shares |
| Susquehanna Portfolio Strategies, LLC | $1,746,449 | 176,231 | 0.46% | Shares |
| Bank of New York Mellon Corp | $1,689,463 | 170,481 | 0.44% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,637,935 | 165,281 | 0.43% | Shares |
| PEAK6 LLC | $1,619,294 | 163,400 | 0.43% | Call option |
| CAXTON ASSOCIATES LLP | $1,532,552 | 154,647 | 0.40% | Shares |
| D. E. Shaw & Co., Inc. | $1,499,938 | 151,356 | 0.39% | Shares |
| Nuveen, LLC | $1,455,234 | 146,845 | 0.38% | Shares |
| MORGAN STANLEY | $1,430,152 | 144,314 | 0.38% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $1,387,400 | 140,000 | 0.37% | Shares |
| JPMORGAN CHASE & CO | $1,368,548 | 134,040 | 0.36% | Shares |
| CITADEL ADVISORS LLC | $1,297,565 | 130,935 | 0.34% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,297,219 | 130,900 | 0.34% | Put option |
| a16z Capital Management, L.L.C. | $1,075,909 | 108,568 | 0.28% | Shares |
| CITADEL ADVISORS LLC | $1,073,253 | 108,300 | 0.28% | Call option |
| Numerai GP LLC | $1,036,606 | 104,602 | 0.27% | Shares |
| AMERICAN CENTURY COMPANIES INC | $974,718 | 98,357 | 0.26% | Shares |
| WOLVERINE TRADING, LLC | $964,467 | 72,900 | 0.25% | Call option |
| Ensign Peak Advisors, Inc | $931,332 | 93,979 | 0.25% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $803,592 | 81,089 | 0.21% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Reshma P. Shetty, Barry Canton | Feb. 14, 2025 | 9.50% | Amendment | · | SEC |
| Jason Kelly ×4 filings | Feb. 14, 2024 | · | Initial filing | · | SEC |
| Reshma Shetty, Bartholomew Canton ×4 filings | Feb. 14, 2024 | · | Initial filing | · | SEC |
| VIKING GLOBAL INVESTORS LP, VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, O. ANDREAS HALVORSEN, DAVID C. OTT, ROSE S. SHABET ×3 filings | March 4, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 17 insiders · 5 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jason R Kelly | Chief Executive Officer & Founder | July 28, 2026 A | 316,483 | 0 | 2 | $-1,374,823 |
| Steven P. Coen | Chief Financial Officer | Aug. 21, 2026 M | 51,851 | 0 | 9 | $-263,897 |
| Mark E. Dmytruk | Chief Financial Officer | May 20, 2025 M | 46,226 | 0 | 0 | $0 |
| Reshma P. Shetty | President & Founder | July 28, 2026 A | 436,422 | 0 | 3 | $-977,101 |
| Marie E. Fallon | Chief Accounting Officer | May 1, 2023 M | 183,010 | 0 | 0 | $0 |
| Christian O Henry | Director | Sept. 15, 2026 S | 19,310 | 0 | 1 | $-35,400 |
| Sri Kosuri | Director | June 11, 2026 A | 24,067 | 0 | 0 | $0 |
| Ross Fubini | Director | June 11, 2026 A | 10,822 | 0 | 0 | $0 |
| Harry Sloan | Director | June 11, 2026 A | 271,418 | 0 | 0 | $0 |
| Shyam Sankar | Director | June 12, 2025 A | 72,372 | 0 | 0 | $0 |
| Kathy Hopinkah Hannan | Director | June 11, 2025 M | 15,003 | 0 | 0 | $0 |
| Myrtle S Potter | Director | June 11, 2025 M | 10,822 | 0 | 0 | $0 |
| Arie Belldegrun | Director | June 13, 2024 A | 194,925 | 0 | 0 | $0 |
| Reshma Kewalramani | Director | June 12, 2024 M | 186,002 | 0 | 0 | $0 |
| Marijn E Dekkers | Director | June 12, 2024 M | 386,480 | 0 | 0 | $0 |
| Eagle Equity Partners III, LLC | Director | Sept. 16, 2021 D | 31,590,948 | 0 | 0 | $0 |
| Barry Canton | 10% owner | July 28, 2026 A | 436,422 | 0 | 3 | $-977,101 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 25 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| THNQ · EXCHANGE TRADED CONCEPTS TRUST | 0.69% | 355,179 NS | July 31, 2026 | N-PORT |
| IDNA · iShares Trust | 0.31% | 115,910 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.08% | 163,763 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.08% | 160,915 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 41,498 SH | Aug. 19, 2026 | Daily |
| IBB · iShares Trust | 0.02% | 379,730 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 22,732 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.01% | 1,228,746 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 549,889 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 274,008 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 112,735 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.00% | 85,360 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 2,967 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.00% | 17,486 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.00% | 4,528 NS | July 31, 2026 | N-PORT |
| VEGN · ETF Series Solutions | 0.00% | 324 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 4,838 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 22,370 SH | Sept. 3, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 66,426 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 29,590 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 5,670 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 10,065 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,489,851 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,264 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 443,818 SH | Sept. 11, 2026 | Daily |
DNA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 10 analysts
SELL
Median target
$7.00
-43.3%
0 0.0%
Strong Buy
0 0.0%
Buy
3 30.0%
Hold
5 50.0%
Sell
2 20.0%
Strong Sell
12-Month Price Target
2 analysts · 2026-10-03Mean target $7.00 -43.3%
Above all targets →
Current price $12.35
Low$5.00
Mean$7.00
High$9.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| DNA | $484M | -1.5 | -25.1% | -183.8% | -55.8% | · |
| FTRE | $1.61B | -1.6 | 1.0% | -36.2% | -171.1% | · |
| BLFS | · | -241.8 | 28.9% | · | · | · |
| AZTA | $1.32B | -23.5 | 3.5% | -9.4% | -3.3% | 45.5% |
| PSNL | $816M | -8.7 | -17.7% | -116.7% | -36.0% | · |
| CYRX | $479M | 6.9 | 12.4% | 44.4% | 15.3% | 47.1% |
| PACB | $565M | -1.0 | 3.9% | -341.5% | -1634.9% | 28.6% |
| CTKB | $649M | 505.0 | 0.52% | -33.0% | -18.5% | 51.8% |
| MLAB | $489M | 73.1 | 3.4% | 2.7% | 3.7% | 63.5% |
| OABI | · | · | · | · | · | · |
| TKNO | $204M | -11.9 | 7.3% | -42.6% | -23.8% | 33.2% |
Latest News Recent headlines mentioning this company
Here's the "Magnificent Seven" Stock Cathie Wood Is Piling Into Now
Nasdaq · 2 months ago
Yahoo announces AI-powered experiences for Yahoo Finance and Yahoo Sports
Yahoo Finance · 3 months, 4 weeks ago
This Warren Buffett Stock Is Beating the S&P 500 in 2026
Nasdaq · 3 months, 4 weeks ago
California Attorney General sues 23andMe successor for 2023 data breach
BBC Business · 4 months ago
Adverts for DNA self-swab kits banned as misleading
BBC Business · 4 months, 2 weeks ago
Jim Cramer on BillionToOne: “I Say Buy It”
Yahoo Finance · 4 months, 2 weeks ago
How sunburn inspired a new way to store energy
BBC Business · 4 months, 3 weeks ago
Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks
ZeroHedge · 4 months, 3 weeks ago
Up 30% in 1 Month, Is Zcash a Better Buy Than Bitcoin?
Yahoo Finance · 5 months, 1 week ago
SCHQ vs. TLT: Same Treasury DNA, Very Different Cost and Duration
Nasdaq · 5 months, 2 weeks ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026